Switching to Tri-Lo-Sprintec from another oral contraceptive Start on the same day that a new pack of the previous oral contraceptive would have started. Implant On the day of removal Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling.
If two active tablets are missed in Week 1 or Week 2 Take the two missed tablets as soon as possible and the next two active tablets the next day. If two active tablets are missed in the third week or three or more active tablets are missed in a row in Weeks 1, 2, or 3 Day 1 start: Throw out the rest of the pack and start a new pack that same day.
Each blister card contains 28 tablets in the following order: 7 gray round, film-coated, biconvex, unscored tablets, debossed with stylized b on one side and on the other side contains 0.
Do not prescribe Tri-Lo-Sprintec to women who are known to have the following conditions: A high risk of arterial or venous thrombotic diseases.
Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions 5. Stop Tri-Lo-Sprintec if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately [see Adverse Reactions 6. If feasible, stop Tri-Lo-Sprintec at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.
Start Tri-Lo-Sprintec no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.
The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.
COCs have been shown to increase both the relative and attributable risks of cerebrovascular events thrombotic and hemorrhagic strokes. This risk increases with age, particularly in women over 35 years of age who smoke.
Use COCs with caution in women with cardiovascular disease risk factors. Liver Tumors Tri-Lo-Sprintec is contraindicated in women with benign and malignant liver tumors [see Contraindications 4 ].
There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.
Some studies suggest that COC use has been associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.
The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions 5.
No drug-drug interaction studies were conducted with Tri-Lo-Sprintec. COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation.
This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increases with use of COCs.
Each active gray tablet contains 0. Inactive ingredients include anhydrous lactose, black iron oxide, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide.
Each active light blue tablet contains 0. Each active blue tablet contains 0. Each white tablet contains only inert ingredients, as follows: anhydrous lactose, hypromellose, magnesium stearate, and microcrystalline cellulose. The structural formulas are as follows:. Counsel patients about the following information: Cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs [see Boxed Warning].
Tri-Lo-Sprintec is not to be used during pregnancy; if pregnancy occurs during use of Tri-Lo-Sprintec instruct the patient to stop further use [see Warnings and Precautions 5. Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed [see Dosage and Administration 2. Use a back-up or alternative method of contraception when enzyme inducers are used with Tri-Lo-Sprintec [see Drug Interactions 7. COCs may reduce breast milk production, this is less likely to occur if breastfeeding is well established [see Use in Specific Populations 8.
Women who start COCs postpartum; and who have not yet had a period, should use an additional method of contraception until they have taken a gray tablet for 7 consecutive days [see Dosage and Administration 2. Amenorrhea may occur. Consider pregnancy in the event of amenorrhea at the time of the first missed period. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles [see Warnings and Precautions 5.
North Wales, PA Rev. What is Tri-Lo-Sprintec? Tri-Lo-Sprintec is a birth control pill oral contraceptive used by women to prevent pregnancy. How does Tri-Lo-Sprintec work for contraception? Version Files Nov 13, 6 current download Sep 29, 5 download Jun 22, 4 download Dec 31, 3 download Aug 20, 2 download Jul 5, 1 download.
NDC 1 2 Starting COCs in women not currently using hormonal contraception Day 1 Start or Sunday Start Important: Consider the possibility of ovulation and conception prior to initiation of this product.
Day 1 Start: Take first active tablet without regard to meals on the first day of menses. Switching to Tri-Lo-Sprintec from another oral contraceptive. Start on the same day that a new pack of the previous oral contraceptive would have started.
Switching from another contraceptive method to Tri-Lo-Sprintec. Start Tri-Lo-Sprintec:. Transdermal patch. On the day when next application would have been scheduled. Vaginal ring. On the day when next insertion would have been scheduled. On the day when next injection would have been scheduled. Intrauterine contraceptive.
On the day of removal. Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling. If one active tablet is missed in Weeks 1, 2, or 3. If two active tablets are missed in Week 1 or Week 2. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs.
May need barrier contraception with Sunday starts or postpartum use see full labeling. Postmenopausal women or nursing mothers: not recommended. See Contraindications. May be antagonized by phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, St.
May be potentiated by atorvastatin, rosuvastatin, acetaminophen, ascorbic acid, or CYP3A4 inhibitors eg, itraconazole, ketoconazole, voriconazole, fluconazole, grapefruit juice. Do not use birth control pills if you are pregnant or if you have recently had a baby.
Taking birth control pills can increase your risk of blood clots, stroke, or heart attack. Smoking can greatly increase your risk of blood clots, stroke, or heart attack.
You should not take birth control pills if you smoke and are over 35 years old. Ethinyl estradiol and norgestimate is a combination birth control pill containing female hormones that prevent ovulation the release of an egg from an ovary.
This medicine also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus. Ethinyl estradiol and norgestimate is used as contraception to prevent pregnancy. There are many available brands of this medicine. Not all brands are listed on this leaflet. Ethinyl estradiol and norgestimate may also be used for purposes not listed in this medication guide.
You are even more at risk if you have high blood pressure, diabetes, high cholesterol, or if you are overweight. Your risk of stroke or blood clot is highest during your first year of taking birth control pills.
Your risk is also high when you restart birth control pills after not taking them for 4 weeks or longer. Your risk increases the older you are and the more you smoke. You should not take combination birth control pills if you smoke and are over 35 years old. Do not use if you are pregnant. Stop using this medicine and tell your doctor right away if you become pregnant, or if you miss two menstrual periods in a row. If you have recently had a baby, wait at least 4 weeks before taking birth control pills.
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed. You may need to use back-up birth control, such as condoms with spermicide, when you first start using this medicine. Follow your doctor's instructions. Take one pill every day, no more than 24 hours apart.
When the pills run out, start a new pack the following day. They have the same active ingredients as Sprintec, and are just as effective as Sprintec, although the pills may look slightly different and there might be differences in cost. But other than that, same stuff. Sprintec is a safe and effective combination birth control pill, and since it's a generic, it's pretty inexpensive, too.
Tri-Sprintec is one of the few birth control pills to have official FDA approval for use specifically to treat problem acne. All that upside could make it the best choice when you're choosing your birth control pill. Contraception: X. Out-of-pocket spending for oral contraceptives among women with private insurance coverage after the Affordable Care Act. July Cochrane Library.
Triphasic versus monophasic oral contraceptives for contraception. Published November 9, Cerel-Suhl S and Yeager B. Family Physician. Update on Oral Contraceptive Pills. Published November 1, Lortscher D et al. Journal of Drugs in Dermatology.
Published June Armstrong C. American Family Physician. Published August 1, Effect of birth control pills and patches on weight.
0コメント